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Copyright © 2010 JCBN Summary Geranylgeranoic acid (GGA) is one of the most potent cancer-preventive acyclic
retinoids. GGA has been shown to induce cell death in human hepatoma-derived HuH-7 cells.
We have recently reported the natural occurrence of GGA and its related compounds in
several medicinal herbs such as turmeric, basil, rosehip, cinnamon and others [Shidoji and
Ogawa, J. Lipid Res., 45: 1092–1103, 2004]. In the present study, we performed oral admin-
istration of turmeric tablets to healthy volunteers in order to investigate bioavailability of
natural GGA. By using liquid chromatography/mass spectrometry, authentic GGA was eluted
at a retention time of around 18 min as a negative ion of m/z 303.4. With healthy volunteers,
plasma GGA was detected prior to the tablet intake and its concentrations were increased
at 2 h after its intake and maintained at higher level until 4 h, suggesting an efficient
bioavailability of preformed GGA in the turmeric tablets through oral administration. These
results indicated that GGA in the turmeric tablet was absorbed as an intact form from
intestinal mucosa. The present study provides a clue to conduct a research for cancer preven-
tive roles of GGA in a number of spices.
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Introduction
The efficacy of a synthetic 20-carbon polyprenoic acid (all-
trans 3,7,11,15-tetramethyl-2,4,6,10,14-hexadecapentaenoic
acid) on prevention of second primary hepatoma has been
proven in a double-blinded and randomized phase II clinical
trial with postoperative hepatoma patients with few side
effects [1], and recently, it was revealed that the polyprenoic
acid significantly increased a 5-year survival rate after a
radical therapy of primary hepatoma in these patients [2].
We have also shown that the polyprenoic acid binds to
cellular retinoic acid binding protein (CRABP) [3] as well
as to nuclear retinoid receptors [4], exerts transcriptional
activation of some hepatocyte-specific genes in hepatoma
cells [5], and has preventive actions in chemical and sponta-
neous hepatocarcinogenesis [6]. In this context, we named
this compound “acyclic retinoid” [7].
Acyclic retinoid induced cell death in human hepatoma-
derived cell lines, HuH-7 and PLC/PRF5, although natural
retinoids such as retinoic acid failed to induce cell death at
least at the same condition [8]. Therefore, we have specu-
lated that acyclic retinoid may have different metabolism
and signalling from retinoic acid in cells and animals, and
may mimic other biological components such as acyclic
diterpenoids, for example, geranylgeranoic acid (GGA),
from which acyclic retinoid, 4,5-dehydroGGA, differs for
the additional double bond at a position between C4 and C5.
GGA has been considered as a synthetic compound for a
long time, but its chemical structure suggests that GGA mayPlasma Geranylgeranoic Acid after Turmeric Intake
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occur as a natural substance in a group of acyclic diterpe-
noids. Recently, we reported the natural occurrence of GGA
in several medicinal herbs (schisandra, licorice, etc.) used
in traditional medicine, Kampo and Ayurveda, as well as
ordinary herbs (turmeric, basil, rosehip, cinnamon, etc.) [9].
In the present study, we examined a bioavailability of
GGA in commercially available turmeric tablets by oral
administration of the tablet to healthy volunteers and liquid




All-trans GGA was obtained from Kuraray (Kurashiki,
Okayama, Japan). n-Hexane, dehydrated diethyl ether, 2 M
sodium hydroxide solution, and 2 M hydrochloric acid were
from Wako Pure Chemical Industries (Osaka, Japan). N-
methyl-N-nitro-N-nitrosoguanidine (MNNG) was purchased
from GL Science Inc. (Tokyo, Japan). Arachidonic acid
(ARA) was from Sigma-Aldrich (St Louis, MO). Methanol,
methanol for HPLC, and ethanol were from Kanto Chemical
Co., Inc. (Tokyo, Japan). Turmeric tablets were obtained
from Yamada Kenkodo (Tokyo, Japan) and milk (Morinaga
Milk Industry Co., Ltd., Tokyo) was purchased from a local
market. One turmeric tablet (0.4 g) contains 0.6 mg protein,
50 mg lipids, 250 mg carbohydrates, and 80 mg curcumin
according to the manufacturer’s specifications.
Study population and design
The study was open, randomized and crossover designed.
Eligible participants were 7 healthy male and female volun-
teers between the ages of 20 and 25 years (23 ± 1, mean ±
SEM). Seven participants, consisting of 4 males and 3
females, received a single oral dose of 6 turmeric tablets
with 200 ml of milk or only milk as control within one
minute and then crossovered after one-week washout. The
study was carried out with approval from the Committee on
Medical Ethics of International Research Center for Tradi-
tional Medicine prior to starting of the study, and Informed
Consent was obtained from the participants in accord with
Helsinki Declaration and following careful explanation of
all study conditions and procedures. The study was con-
ducted at the International Research Center for Traditional
Medicine from June to August in 2005. The study protocol
was also approved by Research Ethics Committee of Siebold
University of Nagasaki.
Blood sampling
Subjects, who had not consumed any turmeric-contained
foods like curry to their knowledge within the previous 3
days and also had fasted since last 9:00 PM, were examined
one by one at each fixed time every 2 min from 9:00 AM
after a 40-min seated rest through discharging urine, in a
quiet, air-conditioned room with temperature maintained at
22–24°C. The study drugs or control were ingested in
30 min after pre-dosing blood samples were collected.
Blood samples were collected 30 min, 1 h, 2 h, 4 h, 8 h,
and 24 h after administration. During the examination, all
subjects had the same menu at lunch (PM 1:30) and dinner
(PM 6:00), and afterwards any food besides water was
not allowed until 24 h-sampling. Sampling protocol was
designed to minimize oxidation after collection. Venous
blood (10 ml) was collected from subjects in heparinized
tubes, maintained at room temperature throughout prepara-
tion. For plasma isolation, blood was centrifuged at 3500
rpm for 10 min at 10°C. Plasma was removed, aliquoted and
stored at −80°C until analysis.
Preparation of plasma extracts
After thawed at room temperature, an aliquot (0.5 ml) of
plasma sample was transferred into a test tube containing
equi-volume (0.5 ml) of ethanol and vortexed vigorously.
After removal of proteins by centrifugation at 2700 rpm for
10 min, 25 μl of 2 M NaOH and 2 ml of n-hexane were
added to the resultant clear supernatants and stirred again.
After separation of the upper organic phase from the lower
water phase by centrifugation (2700 rpm, 10 min), the upper
phase was saved as a crude lipid fraction, which was stored
at −20°C until use. After neutralized with 2 M HCl (50 μl),
the lower aqueous phase was added to n-hexane (2 ml) and
vortexed strongly. After centrifugation, the upper organic
phase was collected and evaporated to dryness. The residues
were dissolved in 0.3 ml of ethanol and used as an acidic
lipid fraction for GGA determination. The recovery of added
standard GGA throughout these processes was in a range of
60–70%.
LC/MS analysis of the plasma extract
HPLC was performed by using a Waters 2690 separation
module (Waters, Milford, MA) equipped with a Cosmosil
reverse-phase 5C18-PAQ column (4.6 mm × 250 mm Nacalai
Tesque, Tokyo, Japan). The mobile phase consisted of 88%
(v/v) methanol aqueous solution at a flow rate of 0.3 ml/min.
1 μl of each sample was injected into the column by the
automatic injector. Inline MS was performed by using a
Waters ZMD 2000 with an electrospray interface in the
negative or positive ion mode, specifically with a capillary
voltage of 3 kV and a cone voltage of 30 V. Dehydrated
nitrogen was used for both cone gas (56 l/h) and desolvation
gas (496 l/h), with the source and desolvation temperatures
being held at 130°C and 350°C, respectively. The data
acquisition program (MassLynx NT, version 3.5, Waters)
was set to scan in the selected ion mode at m/z 303.4 nega-
tive ions.M. Mitake et al.
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Methylation with diazomethane
The methylation with diazomethane was conducted with
authentic GGA and plasma extracts in the same procedure.
An aliquot of samples was dried under nitrogen, and the
residues were treated with diazomethane, Diazomethane
was released from 130 mg of MNNG by addition of 0.5 ml
water and 0.6 ml 5 M NaOH, and the generated gas was
trapped in 3.0 ml of ice-cold diethyl ether in a diazomethane
generator (millimole size, GL Sciences, Tokyo, Japan). A
sufficient amount (0.5 ml) of the diazomethane-ether solu-
tion was added to the dry residues, and the mixture was
left for 30 min at room temperature. After the methylation
reaction, the solvent was redissolved in 250 μl of ethanol.
The methylated plasma extracts were analyzed on LC/MS in
comparison with the methylated GGA standard.
Quantitative measurement of GGA by selected ion recording
The standard curve for quantification of GGA was made
from mass peak areas of ion plots in the selected ion
recording (SIR) at m/z 303.4 of the negative ion using
MassLynx NT software, version 3.5. GGA standard solution
(1.0 μl) was injected into the reverse-phase column ranging
in amounts from 0.1 ng to 1 ng, with the regression values
for R2 = 0.9996 and detected by LC/MS. The concentrations
of GGA in plasma extracts were calculated from the mean
mass area by SIR-LC/MS chromatogram with triplicate
injection based upon the standard curve.
Determination of GGA in turmeric tablets and cow milk
Turmeric tablets were extracted with ethanol at 4°C
overnight. After evaporation to dryness, the residues were
dissolved in ethanol. An aliquot (0.5 ml) of milk was trans-
ferred into a test tube containing equi-volume (0.5 ml) of
ethanol and vortexed vigorously. After removal of proteins
by centrifugation at 2700 rpm for 10 min, 25 μl of 2 M
NaOH and 2 ml of n-hexane were added to the resultant
clear supernatants and stirred again. After removing the
upper organic phase from the lower water phase by centrifu-
gation (2700 rpm, 10 min) and neutralize with 2 M HCl
(50 μl), the lower aqueous phase was added to n-hexane
(2 ml) and vortexed strongly. After centrifugation, the upper
organic phase was evaporated to dryness and dissolved in
ethanol and used for GGA determination.
The ehanolic solutions of turmeric tablets and cow milk
were analyzed by LC/MS same procedure as plasma GGA.
Results
GGA in commercially available turmeric tablets and cow
milk
At the initial place of the present study, we measured
GGA contents in commercially available turmeric tablets
and cow milk. As shown in Fig. 1A, authentic GGA and
ARA were eluted at around 18 min and 14 min, respectively,
when mass ions of m/z(−) = 303.4 were traced on LC/MS.
Fig. 1B clearly describes that cow milk contained free ARA,
a concentration of which was calculated to be 0.3 μg/ml
from its peak area. On the other hand, cow milk obtained
from a supermarket contained no detectable amount of GGA
in our assay system (Fig. 1C) so that cow milk was used as
negative control food for the present human study.
In contrast, a major peak of m/z(−) = 303.4 was eluted at
around 5 min with the extract of the turmeric tablet
(Fig. 1D), indicating that no free ARA nor GGA were major
constituents of the turmeric tablet extract. However, a
discrete peak became visible at around RT of authentic
GGA when the same chromatogram was expanded by 5-fold
in y-axis (Fig. 1E). Furthermore, this minor peak was
precisely cochromatographed with authentic GGA added
internally (Fig. 1F), indicating that a minor peak of m/z(−)=
303.4 represents natural GGA in the turmeric tablets. The
content of GGA in the turmeric tablets was calculated to be
0.28 ± 0.22 μg/tablet, consistent with our previous study [9]
in which GGA contents were found highest in turmeric.
Detection of endogenous GGA in human plasma
Fig. 2 shows the elution profiles of m/z(−) 303.4 in SIR
mode with the acidic lipid extracts of human plasmas before
and after oral administration of the turmeric tablets or cow
milk. In a routine analysis of m/z 303.4 SIR, a major single
peak of ARA was easily confirmed, but other distinct peak
was barely detectable in human plasma before the turmeric
intake (Fig. 2A). However, on the expanded scale of y-axis
in the same LC/MS chromatogram, a tiny but discrete peak
of m/z(−) = 303.4 appeared at an RT of 18 min right after
the descending slope of ARA peak (Fig. 2D), corresponding
to standard GGA. Furthermore, the area of this peak was
apparently increased in 2 h after the turmeric intake
(Fig. 2E), although it is difficult to recognize a peak of GGA
in ARA-scale chromatogram (Fig. 2B). These data suggest
that the preformed GGA in the turmeric tablet may be
rapidly absorbed through intestinal wall and appeared in
peripheral circulation as its intact form which might be
bound to albumin.
In a sharp contrast, no increase in the peak area of GGA
was detected after the cow milk intake, as shown in Fig. 2F.
There was also no increase in the peak area of ARA in 2 h
after the intake of cow milk (Fig. 2C).
Changes in plasma concentrations of GGA after intake of
turmeric tablets
Because the basal levels (7.5 – 15.5 ng/ml) of plasma
GGA were variable among the individual volunteers, time-
dependent changes in plasma GGA and ARA concentrations
after the intake of the turmeric tablet (Fig. 3A) or cow milk
(Fig. 3B) were plotted as % of their each basal level. PlasmaPlasma Geranylgeranoic Acid after Turmeric Intake
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GGA concentrations were significantly increased in 2 h after
the intake of the turmeric tablets and were maintained at
higher level until 4 h, and returned to the basal levels at 8 h
(Fig. 3A). Plasma concentrations of free ARA in the same
plasmas, however, stayed unchanged after the turmeric
intake.
On the contrary, plasma GGA and ARA concentrations
were in the range of the basal levels with a slight deviation
after the milk intake (Fig. 3B).
Discussion
In the present study, we were able to detect endogenous
GGA in human plasma of healthy volunteers for the first
time. In addition, we could also demonstrate that plasma
GGA concentration was increased after oral administration
of a commercially available turmeric tablet.
A placebo-controlled double-blinded randomized clinical
trial revealed the efficacy of 1-yr administration of 4,5-
dehydroGGA to the post-operative patients in 5-yr preven-
tion of second primary hepatoma [8]. We have also shown
that other GGA derivatives including 14,15-dihydroGGA,
2,3-dihydroGGA and GGA itself were the same potent
inducers of cell death in hepatoma cells as 4,5-dehydroGGA
[9]. And most importantly, GGA has recently been found as
a natural constituent of several medicinal herbs including
turmeric [9]. The present study additionally confirmed that
natural GGA was in the extract of a commercially available
turmeric tablet, which is consistent with this previous
finding. Therefore, we used a commercial turmeric tablet as
a GGA source in the present human study. At the initial point
of the present study, we had checked the contents of GGA in
several turmeric tablets and capsules made by 4 companies.
The tablet used in the present study was the highest in GGA
contents and no GGA was detected in tablets from other 2
companies.
We were able to detect the basal levels of GGA in human
plasma for the first time. Although we are unaware of where
plasma free GGA was from and what it was derived from,
we have found geranylgeraniol (GGOH) and geranylgeranyl
pyrophosphate (GGPP) in ordinary foods like polished rice,
a principal food for Japanese (manuscript in preparation).
Fig. 1. LC/MS elution profiles of selected ion chromatograph (negative ions at m/z 303.4) of turmeric tablets and cow milk extracts.
A: Authentic GGA and ARA were eluted at the RT of 17.29 min and 13.78 min, respectively. B: A major component in the
acidic lipid fraction of the commercial cow milk was eluted at the same RT as that of authentic ARA. C: The 5-fold expanded
version (y-axis) of the chromatogram in panel B is shown to demonstrate no detectable GGA in the cow milk extracts. D: The
acidic lipid fraction of the turmeric tablet was eluted to show no detectable ARA. E: The 5-fold expanded version (y-axis) of the
chromatogram in panel D is to demonstrate a distinct peak of GGA. F: The cochromatogram of standard GGA with the acidic
lipid fraction of the turmeric tablet is shown at the same scale as panel E. The down-pointing black arrows indicate the elution
position of authentic GGA.M. Mitake et al.
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Fig. 2. LC/MS analysis of plasma extracts before and after oral administration of turmeric tablets or milk. LC/MS analysis was
conducted as described in the “Materials and Methods” section. A and D: Elution profiles of m/z(−) 303.4 in the acidic lipid
fraction from plasma taken before oral administration of the turmeric tablet. The 50-fold expanded version in y-axis of the
chromatogram in panel A is depicted in panel D to demonstrate circulating GGA. B and E: Elution profiles of m/z(−) 303.4 in
the acidic lipid fraction from plasma taken 2 h after oral administration of the turmeric tablet. The 50-fold expanded version in
y-axis of the chromatogram in panel B is depicted in panel E to demonstrate the increased amount of circulating GGA. C and F:
Elution profiles of m/z(−) 303.4 in the acidic lipid fraction from plasma taken 2 h after oral administration of the cow milk. The
50-fold expanded version in y-axis of the chromatogram in panel C is depicted in panel F to demonstrate no increase in amount
of circulating GGA. MA, mass area.
Fig. 3. Changes in the concentrations of plasma GGA and ARA after oral administration of the turmeric tablets or cow milk. LC/MS
analysis of plasma GGA and ARA was conducted as described in the “Materials and Methods” section. Time-dependent
changes in plasma GGA and ARA concentrations after the intake of the turmeric tablets (A) or cow milk (B) were plotted as %
of their each basal level of circulating GGA in individuals. Each symbol represents the mean ± SE (n =4 ) .Plasma Geranylgeranoic Acid after Turmeric Intake
Vol. 46, No. 3, 2010
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Therefore, one can easily speculate that GGOH and GGPP
in foods daily ingested may be oxidatively metabolized
to GGA in our body. In fact, bovine intestinal alkaline
phosphatase catalyzed dephosphorylation of GGPP to
GGOH and an in vitro incubation of GGOH with NAD(P) in
rodent liver homogenates produced GGA by stoichiometry
(manuscript in preparation). In this context, the “endo-
genous” GGA in human plasma, which we found by LC/MS
technique, might be derived from natural food resources.
This may be a reason why the basal levels of GGA varied
among the individuals who are usually eating GGA-rich or
GGA-poor foods. The same thing is true with phytanic acid,
perhydroGGA or fully-saturated GGA. The elevated level of
phytanic acid in plasma is used for diagnosis of peroxisomal
disorders [10] including Zellweger syndrome [11]. Phytanic
acid is well known to be derived from phytol, a breakdown
product of chlorophyll. Phytol is not produced in the human
gut, but micro-organisms present in the gastrointestinal
system of ruminants can break down chlorophyll to release
phytol, which is then converted into phytanic acid in our
body.
The average basal level of plasma free GGA was around
0.05 μM concentration, which is in a range of one-hundredth
of the concentration (5 μM) inducing cell-death in human
hepatoma-derived HuH-7 cells in vitro [12]. Although we
never tried repeated administration of turmeric tablets in
the present study, a single administration of the tablet
made a slight increase of plasma GGA up to 0.07 μM, which
concentration is also far below the toxic concentration
against hepatoma cells. It may be worthwhile to mention that
the ingested GGA may be selectively taken up and accumu-
lated in tumor cells, because tumor cells show the enhanced
expression of CRABP, to which GGA may be bound [3].
Meanwhile, we must also describe an apparent rebounded
increase of plasma GGA concentrations at 24 h after tablet
intake (Fig. 3A), suggesting that the upregulation of plasma
GGA concentrations may not be merely due to intestinal
absorption of exogenous GGA, but also due to changes of
GGA metabolism after turmeric intake.
In the present study, we tested bioavailability of pre-
formed GGA ingredient in a turmeric tablet which is
commercially available in a regular drug store. As a result, a
postprandial increase in plasma free GGA concentration
was observed at 2 h after the turmeric intake. Although the
time of peak plasma fatty acid concentration generally
occurs 2 to 6 h following dose in normal healthy women
[13], the time at which maximum concentration of coenzyme
Q10 (CoQ10) occurs in the plasma after supplementation
with CoQ10 soft gel capsule is 6 h or after [14, 15]. In this
context, GGA may be classified into fatty acids rather than
terpenoids, in terms of molecular mechanism of intestinal
absorption.
We measured only free form of GGA in plasma, but
GGA can be esterified with glycerol, because GGA shares
biological and chemical characteristics of branched chain-
and polyunsaturated fatty acids. Therefore, we are now
going to establish an assay system for the putative esterified
forms of GGA in plasma. Furthermore, one should be
cautious about other water-soluble metabolites of GGA
such as its glucronides and sulfides, because plaunotol
(18-hydroxygeranylgeraniol) and 18-hydroxyGGA were
reported to be conjugated with β-glucronic acid in rats
and dogs [16]. We also know that dose-response type experi-
ment of clinical trial is certainly required to establish the
bioavailability of GGA in foods for the future experiment.
In conclusion, the results of the present study show that
LC/MS analysis detected GGA in human plasma and the
concentration of circulating GGA was increased after oral
administration of a turmeric tablet, which contained pre-
formed GGA.
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